CureVac NV (CVAC) Stock
CVAC is no longer traded. CureVac NV was acquired by BioNTech (BNTX) in January 2026.
Prices on this page are historical; the last trade was January 5, 2026 at $4.66.
See BioNTech (BNTX) stock →CureVac NV stock price history
CVAC final trading statistics
- Final close
- $4.66
- Final trading day
- Jan 5, 2026
- Market cap at delisting
- $1.05B
- Shares outstanding
- 225.17M
- Final 52-week range
- $2.48 – $5.72
- Avg. volume (final 3 mo.)
- 1,132,069
- All-time high (split-adj.)
- $136.27 · Dec 2020
- All-time low (split-adj.)
- $2.31 · Apr 2024
- Return since IPO
- -91.7%
- Beta
- 1.84
- Book value / share
- $5.63
- Price / book
- 0.83
CureVac NV annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $535.18M | $162.2M | $0.62 |
| FY2023 | $53.76M | -$260.2M | -$1.21 |
| FY2022 | $67.42M | -$249.0M | -$3.23 |
| FY2021 | $102.99M | -$411.7M | — |
| FY2020 | $48.90M | -$129.1M | -$0.91 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In addition, the company offers The RNA Printer, a downsized, integrated, and highly automated process for manufacturing of mRNA vaccines and therapeutics. Further, it develops prophylactic vaccine lead candidate that addresses urinary tract infections targeting uropathogenic E. coli (UPEC) bacteria; vaccine candidates CV0601 and CV0701, which are in phase 2 clinical study against SARS-CoV-2; vaccines for off-the-shelf and fully personalized cancer precision immunotherapies in oncology; and CVGBM for treating cancer. Additionally, the company develops, manufactures, and commercializes mRNA vaccines targeting SARS-CoV-2 variants; antigen cancer precision immunotherapy candidate that targets squamous non-small cell lung cancer; and antigen cancer precision immunotherapy candidate CVGBM that is tested in patients with surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. CureVac N.V. was incorporated in 2000 and is headquartered in Tübingen, Germany.
CureVac NV stock FAQ
What happened to CureVac NV stock?
CureVac NV was acquired by BioNTech (BNTX) in January 2026. CVAC stock stopped trading on the Nasdaq, with a final close of $4.66 on January 5, 2026.
Is CVAC stock still trading?
No. CVAC was delisted from the Nasdaq in January 2026 and no longer trades on a U.S. exchange.
What was the last price of CVAC stock?
CVAC closed at $4.66 on its final trading day, January 5, 2026, for a market value of about $1.05B.
What were CureVac NV's revenue and earnings in its last full fiscal year?
CureVac NV reported revenue of $535.18M and net income of $162.2M in fiscal 2024, its last full year as a public company.
When did CureVac NV go public?
CureVac NV stock began trading on August 14, 2020.